Novolog Mix 70/30 Penfill is a drug owned by Novo Nordisk Inc. It is protected by 7 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 19, 2017. Details of Novolog Mix 70/30 Penfill's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5866538 (Pediatric) | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) |
Expired
|
| US5866538 | Insulin preparations containing NaCl |
Jun, 2017
(7 years ago) |
Expired
|
|
US5618913 (Pediatric) | Insulin analogues |
Dec, 2014
(9 years ago) |
Expired
|
| US5618913 | Insulin analogues |
Jun, 2014
(10 years ago) |
Expired
|
| US5834422 | AspB28 insulin compositions |
Sep, 2013
(11 years ago) |
Expired
|
| US5840680 | ASPB28 insulin crystals |
Sep, 2013
(11 years ago) |
Expired
|
| US5547930 | AspB28 insulin crystals |
Sep, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Novolog Mix 70/30 Penfill is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Novolog Mix 70/30 Penfill's family patents as well as insights into ongoing legal events on those patents.
Novolog Mix 70/30 Penfill's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Novolog Mix 70/30 Penfill's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 19, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Novolog Mix 70/30 Penfill Generics:
There are no approved generic versions for Novolog Mix 70/30 Penfill as of now.
Alternative Brands for Novolog Mix 70/30 Penfill
Novolog Mix 70/30 Penfill which is used for managing diabetes mellitus., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc |
| |||||||
| Sanofi Aventis Us |
| |||||||
About Novolog Mix 70/30 Penfill
Novolog Mix 70/30 Penfill is a drug owned by Novo Nordisk Inc. It is used for managing diabetes mellitus. Novolog Mix 70/30 Penfill uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant as an active ingredient. Novolog Mix 70/30 Penfill was launched by Novo Nordisk Inc in 2001.
Approval Date:
Novolog Mix 70/30 Penfill was approved by FDA for market use on 01 November, 2001.
Active Ingredient:
Novolog Mix 70/30 Penfill uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant ingredient
Treatment:
Novolog Mix 70/30 Penfill is used for managing diabetes mellitus.
Dosage:
Novolog Mix 70/30 Penfill is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) | INJECTABLE | Discontinued | SUBCUTANEOUS |